The silent deterioration of our internal energy systems has quietly become the primary architect of the global health crisis, manifesting as a collection of seemingly unrelated diseases. For decades, the medical establishment viewed heart disease, type 2 diabetes, and chronic kidney failure as
Faisal Zain has navigated the complex intersection of medical device innovation and digital health for years, witnessing firsthand how the industry struggles to turn fragmented data into life-saving treatments. As Big Tech players like Amazon and Google move deeper into the life sciences, the
Cervical cancer is on the brink of elimination in Australia, yet thousands of women still face stagnant survival when the diagnosis is uterine, ovarian, vulvar, vaginal, or placental, and that paradox now defines both the opportunity and the risk for a health system known for turning science into
Carla Gairy sits down with Faisal Zain, a healthcare expert whose career in medical technology and device manufacturing has shaped a rigorous, systems-first approach to care delivery. He brings a builder’s mindset to Medicaid’s toughest edge cases—children in foster care and kids with complex condi
Market Outlook: A One-Time Edit Reshapes the HAE Playbook A single gene edit cutting hereditary angioedema attacks by 87% is forcing the HAE market to rethink risk, price, and care delivery all at once, and the clock on first-in-class approval has started. The headline efficacy for Intellia
Volunteers gave blood, scans, and the secrets of their DNA to help science cure disease, yet the same data traveled across borders, landed on an e-commerce site, and revealed how easily controlled access can turn into copyable stock that outlives promises, policies, and platforms. The UK Biobank
